Price data is not available
Moleculin Biotech Inc
MBRXNASDAQ
Moleculin Biotech fell 28.3% from $12.08 to $8.66, behind the S&P 500's +10.5%. Its worst day was Jul 31 (−60.8%), and its low came Oct 16 at $0.28.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-17.00 missed the $-5.50 estimate on $0.00 revenue.
−4.4% · S&P 500 0.0%
EPS of $-26.06 missed the $-6.77 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−1.0% · S&P 500 −0.5%
EPS of $-3.54 missed the $-1.67 estimate on $0.00 revenue.
−4.1% · S&P 500 −1.2%
EPS of $-1.40 beat the $-1.55 estimate on $0.00 revenue.
+7.2% · S&P 500 −0.2%
Moleculin Biotech closed at its lowest level of the year, 97.7% below where the year started.
−24.2% · S&P 500 −1.1%
Where it ended: a close of $8.66 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-9.07).
Nothing in the past 12 months.
All MBRX dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MBRX and SPY from Benzinga historical bars. Not investment advice.
